And so, another working will soon draw to a close. Not a moment too soon, yes? Although this has been an unusual week on the side of the pond, where a holiday prompted many to disappear or kick back just a little. Nonetheless, we still have weekend daydreams to cherish. Our agenda is rather modest. We plan to spend time with our short person, catch up on some reading, and take a few naps. And what about you? Summer is here and the time is right for enjoying the great outdoors or planning a getaway. You could also make time for someone special. Or place bets on who will next be forced to depart from “the swamp.” Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Payments to physicians after they sat on Food and Drug Administration advisory panels have gone largely unnoticed and entirely unpoliced, Science finds. In examining compensation records from drug makers to physicians who advised the FDA on whether to approve 28 psychopharmacologic, arthritis, and cardiac or renal drugs between 2008 and 2014, there were widespread after-the-fact payments or research support to panel members. But agency safeguards against potential conflicts of interest are not designed to prevent such future financial ties.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Let’s assume Takeda gets sixty million dollars (6 tens) for it’s HQ complex. Does that raise funds – yes and way to much for me to turn down. That said, when the tab for Shire is $62 BILLION USD, that sale will defray it by ….. just under 1/10th of 1 pct. (Well, it’s something symbolic but scarcely ‘material’ IMHO.)

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy